Innovation for Improved Wound Management
Carefully constructed with native bovine collagen fibers and elastin, MatriDerm® is a one-of-a-kind single-use acellular dermal matrix.
Vascularization in 3-7 Days
Only Matrix With Elastin
Less Than 5% Infection Rate
Expect Better.
Matriderm is clinically proven to accelerate tissue regeneration and improved outcomes. MatriDerm is indicated for use in the management of wounds including:
Wounds
Partial and full-thickness wounds
Chronic Wounds
Pressure ulcers, venous ulcers, diabetic ulcers
Surgical Wounds
Donor sites/grafts, post-Mohs surgery, post-laser surgery, wound dehiscence
Burns
Partial thickness burns
Traumatic Wounds
Abrasions, lacerations, and skin tears
Other Wounds
Draining wounds
See the MatriDerm Difference
Pediatric Scald Burn
Courtesy of J . Lee, MD, Seoul, S . Korea
Chronic Venous Ulcer
Type of Wound: Chronic venous ulcer
Etiology: Venous insufficiency with a 5-year open wound on the medial and lateral side of the lower left leg
Patient: 51-year-old male
Courtesy of F . Tostes, MD, Rio Grande do Sul, Brazil
V.A.C. Therapy and GranuFoam by Kinetic Concept, Inc (KCI)
Necrotizing Fasciitis
Type of Wound: Almost complete circumferential loss of skin and soft tissue of lower leg with exposed gastrocnemius tendons without vascularity
Etiology: Life and limb-saving debridement for necrotizing fasciitis in a type 1 diabetic
Patient: 45-year-old male
Courtesy of I . Younis, MBBCh, MRCS (Eng), MSc, FRCS (Plast), London, UK
Crush Trauma
Type of Wound: Deep soft tissue defect with involvement of the fascia, right lower leg
Etiology: Crush trauma by a school bus
Patient: 7-year-old boy
Courtesy of M. Öhlbauer, B. Wallner and M. Militz, MD, Murnau, Germany
Infected Dog Bite
Type of Wound: Infected, necrotic full-thickness wound at the dorsum of the hand
Etiology: Dog bite
Patient: 64-year-old female
Courtesy of U. Hug, MD, Luzern, Switzerland
Groundbreaking Results for Better Patient Outcomes
Vascularization Rates
MatriDerm1
3-7 days
Leading
Bilayer Matrix2
21-28 days
28 days
Infection Rates
| MatriDerm7,8 | 0-5% |
|---|---|
| Leading Bilayer Matrix9 | 14-55% |
| Leading Synthetic Matrix10,11 | 13.3-40% |
In a 3-month follow-up study, MatriDerm-grafted patients showed no unstable scars or blisters and had a full range of motion and excellent skin pliability of grafted areas.”
– Rnjak et. al. Tissue Engineering Part B: Vol 17, Num 2, 2011, DOI: 10.1089/ten.teb.2010.045
In a 3-month follow-up study, MatriDerm-grafted patients showed no unstable scars or blisters and had a full range of motion and excellent skin pliability of grafted areas.”
– Rnjak et. al. Tissue Engineering Part B: Vol 17, Num 2, 2011, DOI: 10.1089/ten.teb.2010.045
Take the Next Step in Improving Your Patients’ Outcomes
MatriDerm stands apart as an industry leader in dermal matrix technology, helping providers accelerate wound management to improve clinical, functional, and aesthetic outcomes. Schedule a demo to learn more about the difference MatriDerm can make for your patients.